ADMA - ADMA Biologics, Inc.
ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
As of May 15, 2026: spot at $8.27, ATM IV 60.2%, net GEX $261.8K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.97B
- P/E Ratio
- 12.14
- Beta
- 0.82
- 52-Week Range
- 7.21-22.37
- CEO
- Adam S. Grossman
- Employees
- 685
- IPO Date
- Oct 17, 2013
- Exchange
- NASDAQ
What ADMA Looks Like to Options Traders Today
IV rank of 13.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($261.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.124) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The ADMA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ADMA overview questions
- What is ADMA?
- ADMA is the ticker symbol for ADMA Biologics, Inc., a listed security. ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. Listed on NASDAQ. ADMA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ADMA options snapshot look like today?
- As of May 15, 2026, the ADMA options snapshot shows spot at $8.27, ATM IV 60.2%, IV rank 13.1%, net GEX $261.8K, expected move 17.26%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ADMA's key statistics?
- ADMA Biologics, Inc. (ADMA) carries a market capitalization of $1.97B, trailing P/E ratio of 12.14, beta of 0.82 relative to the broader market, 52-week range of 7.21-22.37. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ADMA belong to?
- ADMA Biologics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ADMA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ADMA data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).